Interviews with participating patients from the VenoValve® U.S. Pivotal Trial ...

Safe, effective one-year outcomes in severe tricuspid regurgitation, enhancing symptoms and reducing admissions.

New research shows that cryoablation is a safe and effective approach to close congenital patent foramen ovale (PFO, a small hole in the heart) in patients with atrial fibrillation (AF) undergoing ...

Step into a life free of leg pain and self-consciousness – from long car rides to warm winter getaways. Board-certified ...

VVeno Medical's NVNO submission of the final module for VenoValve’s Premarket Approval (PMA) application to the FDA represents a crucial milestone in addressing unmet needs in the treatment of Chronic ...

Company to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ...

November 20, 2024—enVVeno Medical Corporation announced 1-year data on all patients from SAVVE, the United States pivotal trial of the company&r ...

The Company is also developing a next-generation, non-surgical transcatheter based replacement venous valve called enVVe, which could appeal to an even larger market in terms of both patients and ...

VVeno Medical (NVNO) has submitted its application with the U.S. Food and Drug Administration seeking approval to market and sell the ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to preliminary ...

Patients who receive a heart valve replacement are well-known to be at a high risk for stroke, blood clots and deep vein ...